• European Commission approves Lilly's Emgality for migraine pharmatimes
    November 22, 2018
    Eli Lilly has confirmed that Emgality, a once-monthly monoclonal antibody injection, has been approved by the European Commission for preventive treatment of migraine in adults who have at least four migraine days per month.
PharmaSources Customer Service